12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Belinostat: Additional Phase II data

Preliminary safety data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat was well tolerated with a favorable safety profile. Grade 3/4 non-hematologic adverse events included asthenia/fatigue, pneumonia, dyspnea, infection, febrile neutropenia, pruritus, deep vein thrombosis (DVT) and hypotension. Grade 3/4 hematologic toxicities were thrombocytopenia, anemia, leukopenia...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >